Coave Therapeutics Advances Novel Gene Therapy for Retinal Vascular Diseases with Superior Suprachoroidal Capsid
核心洞察
Coave Therapeutics (搜索)' lead suprachoroidal capsid coAAV-SCS-01 (搜索) demonstrated up to 26x superior performance compared to other capsids in targeting retinal cells in non-human primate studies.
The company has nominated CoTx-101 (搜索) as its lead gene therapy program for wet age-related macular degeneration (搜索) and diabetic macular edema (搜索), combining durability, efficacy and safety.
CoTx-101 (搜索) aims to address the significant treatment burden of current anti-VEGF (搜索) therapies, which require repeated injections every 4-12 weeks and see over 40% patient discontinuation after one year.
Coave Therapeutics (搜索) has unveiled breakthrough data demonstrating the superiority of its novel suprachoroidal capsid technology for treating retinal vascular diseases (搜索), positioning the company to transform gene therapy approaches for conditions affecting millions of patients worldwide.
Superior Performance in Preclinical Studies
The company's lead suprachoroidal capsid, coAAV-SCS-01 (搜索), demonstrated remarkable performance in two comparative studies conducted in non-human primates. In the first study testing against first and second-generation capsids including AAV2 (搜索), AAV3B, AAV.7m8, AAV.v128 and AAV8 (搜索) in cynomolgus macaques, coAAV-SCS-01 outperformed all other capsids by up to 26x in targeting RPE-choroid (搜索) and retinal cells while being de-targeted from off-target areas such as the iris-ciliary body.
A second study confirmed coAAV-SCS-01 (搜索)'s superiority over AAV8 (搜索), a clinical benchmark, demonstrating improved transduction of both RPE-choroid (搜索) and retinal photoreceptor cells. The capsid also showed an improved safety profile with de-targeting from the anterior segment of the eye and immune evasion properties, suggesting potential for safe second-eye treatment.
Lead Program Nomination for Retinal Vascular Diseases
Building on these promising preclinical results, Coave has nominated CoTx-101 (搜索) as its lead gene therapy program for treating retinal vascular diseases (搜索), including wet age-related macular degeneration (搜索) (wAMD) and diabetic macular edema (搜索) (DME). The therapy combines Coave's proprietary suprachoroidal vector (coAAV-SCS) with two clinically validated biologics targeting the angiogenesis pathway (搜索).
CoTx-101 (搜索) represents a potential breakthrough by combining three essential attributes that current therapies have yet to achieve simultaneously: durability, efficacy and safety. The treatment aims to deliver durable vision gains via an in-office procedure, offering high clinical benefit with reduced treatment burden.
Addressing Significant Unmet Medical Need
The current standard of care for retinal vascular diseases (搜索) relies on anti-VEGF (搜索) biologics requiring repeated injections every 4-12 weeks, often for life. This creates a substantial treatment burden, with more than 40% of patients discontinuing treatment after the first year, leading to uncontrolled disease progression and further vision loss.
Globally, an estimated 10-20 million adults live with wAMD and 37 million people with DME, with many more affected by other retinal vascular diseases (搜索). Coave's suprachoroidal delivery approach enables an in-office procedure targeting the back of the eye, potentially providing a routine treatment as simple as an anti-VEGF (搜索) injection.
Development Timeline and Technology Platform
Coave plans to complete target product profile validating non-human primate studies of CoTx-101 (搜索) in 2026, with the goal of being IND-ready in 2027. The company's proprietary ALIGATER™ platform enables conjugation of targeting ligands on AAV vectors, offering superior delivery efficiency, tissue specificity and safety profile while streamlining manufacturing by avoiding prior AAV capsid modifications.
"These data confirm that our suprachoroidal capsid, coAAV-SCS-01 (搜索), delivers on all key metrics versus existing first and second-generation capsids," said Rodolphe Clerval, Chief Executive Officer of Coave Therapeutics (搜索). "coAAV-SCS-01's greatly enhanced tissue targeting and transduction, improved safety, and the potential for second-eye treatment could provide a breakthrough for gene therapies in retinal vascular disease."
The company's delivery-first approach to targeted gene therapy creates precision vectors that are highly tissue-specific, precisely delivered and safer than traditional approaches, with potential applications across multiple therapeutic areas beyond ophthalmology.